These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 14573330)

  • 1. Efficacy of low-dose spironolactone in subjects with resistant hypertension.
    Nishizaka MK; Zaman MA; Calhoun DA
    Am J Hypertens; 2003 Nov; 16(11 Pt 1):925-30. PubMed ID: 14573330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.
    Ghazi L; Dudenbostel T; Lin CP; Oparil S; Calhoun DA
    J Hypertens; 2016 May; 34(5):1005-10. PubMed ID: 26886564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose and very low-dose spironolactone in combination therapy for essential hypertension: evaluation by self-measurement of blood pressure at home.
    Hanazawa T; Obara T; Ogasawara K; Shinki T; Katada S; Inoue R; Metoki H; Asayama K; Kikuya M; Ohkubo T; Mano N; Imai Y
    Clin Exp Hypertens; 2011; 33(7):427-36. PubMed ID: 21777149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.
    Bomback AS; Muskala P; Bald E; Chwatko G; Nowicki M
    Clin Nephrol; 2009 Dec; 72(6):449-56. PubMed ID: 19954722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.
    Lim PO; Jung RT; MacDonald TM
    Br J Clin Pharmacol; 1999 Nov; 48(5):756-60. PubMed ID: 10594479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
    Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
    Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension.
    Abolghasmi R; Taziki O
    Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):75-8. PubMed ID: 21196617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension.
    Williams B; MacDonald TM; Caulfield M; Cruickshank JK; McInnes G; Sever P; Webb DJ; Salsbury J; Morant S; Ford I; Brown MJ
    BMJ Open; 2015 Aug; 5(8):e008951. PubMed ID: 26253568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
    Hood SJ; Taylor KP; Ashby MJ; Brown MJ
    Circulation; 2007 Jul; 116(3):268-75. PubMed ID: 17606839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
    Tytus RH; Burgess ED; Assouline L; Vanjaka A
    Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES).
    Pitt D
    Eur Heart J; 1995 Dec; 16 Suppl N():107-10. PubMed ID: 8682055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
    Browne GA; Griffin TP; O'Shea PM; Dennedy MC
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the aldosterone:renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study.
    Parthasarathy HK; Alhashmi K; McMahon AD; Struthers AD; Connell JM; McInnes GT; Ford I; MacDonald TM
    BMC Cardiovasc Disord; 2007 May; 7():14. PubMed ID: 17490489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker.
    Yutaka M; Mifune M; Kubota E; Itoh H; Saito I
    Clin Exp Hypertens; 2009 Nov; 31(8):648-56. PubMed ID: 20001457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of spironolactone in the treatment of patients with refractory hypertension.
    Ouzan J; Pérault C; Lincoff AM; Carré E; Mertes M
    Am J Hypertens; 2002 Apr; 15(4 Pt 1):333-9. PubMed ID: 11991219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension.
    Oxlund CS; Cangemi C; Henriksen JE; Jacobsen IA; Gram J; Schousboe K; Tarnow L; Argraves WS; Rasmussen LM
    J Hum Hypertens; 2015 Jan; 29(1):28-32. PubMed ID: 24739800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [On the way to achieve hypertension treatment goals: results of the open observational program AESCULAP (exforge--clinical safety and efficiency of using a double combination of antihypertensive drugs in patients with uncontrolled blood pressure)].
    Chazova IE; Martynyuk TV
    Ter Arkh; 2013; 85(9):35-45. PubMed ID: 24261228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.